{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:29:35Z","timestamp":1794356975087,"version":"4.9.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01406-6","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T17:51:32Z","timestamp":1762278692000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Correspondence on: Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score\u2013matched study"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5377-9252","authenticated-orcid":false,"given":"Luis E.","family":"Aguirre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7526-2633","authenticated-orcid":false,"given":"Richard M.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7865-2306","authenticated-orcid":false,"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"1406_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01245-5","volume":"15","author":"A Bataller","year":"2025","unstructured":"Bataller A, Sasaki K, Urrutia S, Montalban-Bravo G, Bazinet A, Chien K, et al. Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score\u2013matched study. Blood Cancer J. 2025;15:50. https:\/\/doi.org\/10.1038\/s41408-025-01245-5.","journal-title":"Blood Cancer J"},{"key":"1406_CR2","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020;383:617\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2012971.","journal-title":"N Engl J Med"},{"key":"1406_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1182\/blood-2020-139492","volume":"136","author":"JS Garcia","year":"2020","unstructured":"Garcia JS, Wei AH, Borate U, Fong CY, Baer MR, Nolte F, et al. Safety, efficacy, and patient-reported outcomes of venetoclax in combination with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: a phase 1b study. Blood. 2020;136:55\u20137.","journal-title":"Blood"},{"key":"1406_CR4","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/ajh.26771","volume":"98","author":"AM Zeidan","year":"2023","unstructured":"Zeidan AM, Borate U, Pollyea DA, Brunner AM, Roncolato F, Garcia JS, et al. A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. Am J Hematol. 2023;98:272\u201381.","journal-title":"Am J Hematol"},{"key":"1406_CR5","doi-asserted-by":"publisher","first-page":"E433","DOI":"10.1002\/ajh.26334","volume":"96","author":"AN Saliba","year":"2021","unstructured":"Saliba AN, Litzow MR, Gangat N, Al-Kali A, Foran JM, Hogan WJ, et al. Outcomes of venetoclax-based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia. Am J Hematol. 2021;96:E433\u201336.","journal-title":"Am J Hematol"},{"key":"1406_CR6","doi-asserted-by":"publisher","first-page":"E185","DOI":"10.1002\/ajh.26504","volume":"97","author":"S Ball","year":"2022","unstructured":"Ball S, Jain AG, Aguirre LE, Al Ali N, Zhang Y, Chan O, et al. Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?. Am J Hematol. 2022;97:E185\u2013E188.","journal-title":"Am J Hematol"},{"key":"1406_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41375-024-02466-6","volume":"39","author":"D Tremblay","year":"2025","unstructured":"Tremblay D, Csizmar C, DiNardo CD, Ball S, Rippel N, Hammond D, et al. Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study. Leukemia. 2025;39:257\u201360. https:\/\/doi.org\/10.1038\/s41375-024-02466-6.","journal-title":"Leukemia"},{"key":"1406_CR8","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"1406_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2025.100116","volume":"2","author":"LE Aguirre","year":"2025","unstructured":"Aguirre LE, Al Ali NH, Ball S, Jain AG, Sallman DA, Kuykendall AT, et al. A Comparative assessment of molecular-based prognostic models in CMML. Blood Neoplasia. 2025;2:100116. https:\/\/doi.org\/10.1016\/j.bneo.2025.100116.","journal-title":"Blood Neoplasia"},{"key":"1406_CR10","unstructured":"ABBVIE provides update on VERONA Trial for newly diagnosed Higher-Risk Myelodysplastic Syndromes. AbbVie News Center. https:\/\/news.abbvie.com\/2025-06-16-AbbVie-Provides-Update-on-VERONA-Trial-for-Newly-Diagnosed-Higher-Risk-Myelodysplastic-Syndromes. Published June 16, 2025."},{"key":"1406_CR11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/cam4.3608","volume":"10","author":"RS Komrokji","year":"2021","unstructured":"Komrokji RS, Al Ali NH, Sallman D, Padron E, DeZern AE, Barnard J, et al. Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium. Cancer Med. 2021;10:447\u201353. https:\/\/doi.org\/10.1002\/cam4.3608.","journal-title":"Cancer Med"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01406-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01406-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01406-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T08:54:08Z","timestamp":1763369648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01406-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1406"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01406-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Luis E. Aguirre reports consultancy for Curio Science, Cardinal Health, Research To Practice. Honoraria from Curio Science, Fast4ward Learning, Cardinal Health, DAVA Oncology. Richard M. Stone reports research funding from Janssen and AbbVie; Consultancy for GlaxoSmithKline, Curis Oncology, Daiichi Sankyo, ENSEM, Epizyme, BerGenBio, AMGEN, Syntrix, Hermavant, Glycomimetrics, CTI Biopharma, Bristol Meyers Squibb, Rigel, Syndax, AvenCell, Takeda, Jazz, Kura Oncology, Lava Therapeutics, Cellarity, Ligand Pharma, Novartis, Aptevo, and Redona therapeutics; Other: DSMB for Epizyme, Syntrix, Takeda, and Novartis. Daniel J. DeAngelo reports consultancy for Kite, Servier, Incyte, Pfizer, Gilead, Novartis, Jazz, Autolos, Amgen, and Blueprint; Honoraria from Amgen and Bristol-Meyers Squibb; Research funding from Servier, Novartis, Glycomimetics, AbbVie, and Takeda; Other: DSMB for MT Sinai MPN Consortium, Fibrogen, Daiichi-Sankyo. Maximilian Stahl reports membership on the Board of Directors or advisory committees for GSK, Rigel, Sobi, Sierra Oncology, Kymera, BMS, and Syndax. No other disclosures were reported.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"192"}}